© 2025 New Hampshire Public Radio

Persons with disabilities who need assistance accessing NHPR's FCC public files, please contact us at publicfile@nhpr.org.
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Win a $15k travel voucher or $10k in cash. Purchase your Holiday Raffle tickets today!

The FDA Just Approved A Major Alzheimer’s Drug. Now What?

Biogen is the maker of aducanumab, which has been the source of much debate amongst Alzheimer's experts.
Biogen is the maker of aducanumab, which has been the source of much debate amongst Alzheimer's experts.

On Monday, the FDA approved aducanumab, a new medication for Alzheimer’s.

It’s the first new drug for the disease in almost two decades and the first to attack the disease process itself, instead of just its symptoms.

But the FDA’s approval comes despite an intense debate over the drug’s efficacy and associated side effects.

From Kaiser Health News:

We discuss what we know about aducanumab and how it will shape the future of Alzheimer’s research and treatment.

Copyright 2021 WAMU 88.5

Kathryn Fink
Kathryn Fink is a producer with NPR's All Things Considered.

You make NHPR possible.

NHPR is nonprofit and independent. We rely on readers like you to support the local, national, and international coverage on this website. Your support makes this news available to everyone.

Give today. A monthly donation of $5 makes a real difference.